Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Feb 4, 2014 (13 years ago)

Alprazolam Extended-Release Tablets

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Failed Dissolution Specifications: Product did not meet specification requirements for dissolution.

Cause type: Dissolution failure

The tablet or capsule did not dissolve within specification. Dissolution controls how much drug the body absorbs; a failure can change the effective dose. All dissolution failure recalls.

What was recalled

Alprazolam Extended-Release Tablets, USP, 3 mg, 60-count tablets per bottle, Rx only, Manufactured by: Actavis Elizabeth LLC, 200 Elmora Avenue, Elizabeth, NJ 07207, NDC 0228-3086-06, UPC 3 0228-3086-06 2.

Affected NDC 0228-3086-06

Compare with the code on your package — it is the most precise check available.

Drug: Alprazolam Category: Mental Health Medication

Recalling firm
Actavis Elizabeth LLC
NDC code
0228-3086-06
Origin
NJ, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-1091-2014 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Alprazolam recalls

See all
Class II · Moderate risk

Xanax XR

Failed Dissolution Specifications

Ongoing Dissolution failure Viatris, Inc. NDC 58151-506-91 D-0444-2026
Class II · Moderate risk

Alprazolam Tab

CGMP Deviations: Downstream recall from Breckenridge Pharmaceuticals, Inc due to potential risk of Cross Contamination.

Terminated Cross-contamination Preferred Pharmaceuticals, Inc. NDC 68788-7596-3 D-0506-2023
Class II · Moderate risk

Alprazolam Tab

CGMP Deviations: Downstream recall from Breckenridge Pharmaceuticals, Inc due to potential risk of Cross Contamination.

Terminated Cross-contamination Preferred Pharmaceuticals, Inc. NDC 68788-7595-3 D-0505-2023
Class II · Moderate risk

Alprazolam Tab

CGMP Deviations: Downstream recall from Breckenridge Pharmaceuticals, Inc due to potential risk of Cross Contamination.

Terminated Cross-contamination Preferred Pharmaceuticals, Inc. NDC 68788-7594-3 D-0504-2023
Class II · Moderate risk

Alprazolam C-IV

CGMP Deviations: Repackaging firm recalling due to potential product cross contamination concerns at the manufacturer.

Ongoing Cross-contamination Direct Rx NDC 72189-121-60 D-0509-2023

Other recalls by Actavis Elizabeth LLC

All 2014 recalls